| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$257.1M | ROE | −60.51% |
| Net Margin | — | ROIC | −122.02% |
| Debt / Equity | 0.24 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $1.38B | Trading Days | 1009 |
| 52W High | 62.75 |
| 52W Low | 5.95 |
| % Off High | −70.18% |
| YTD | 41.96% | 1Y | −65.65% |
| 3Y | −69.46% | Since incept. (ann.) | 36.00% |
| Ann. Volatility (1Y) | 119.04% | Ann. Volatility (3Y) | 83.40% |
| Sharpe (1Y) | 0.51 | Sharpe (3Y) | 0.34 |
| Max Drawdown (1Y) | −89.93% | Max Drawdown (3Y) | −90.22% |
| Beta (3Y, vs SPY) | 0.07 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.42B | — |
| PRGO | PERRIGO Co plc | $1.43B | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.46B | — |
| CMPS | COMPASS Pathways plc | $1.46B | — |
| HROW | HARROW, INC. | $1.47B | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.48B | 30.6 |
| XNCR | Xencor Inc | $1.48B | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.28B | — |
| ARDX | ARDELYX, INC. | $1.26B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| SEPN | Septerna, Inc. | $1.53B | — |
